ReviewIntestinal Failure (New York, N.Y.)
Effectiveness, safety, and quality of life outcomes of teduglutide treatment in adult patients with short bowel syndrome-associated intestinal failure: A systematic literature review of real-world studies.
Review in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Short bowel syndrome-associated intestinal failure (SBS-IF) results from a reduction in the small intestine length, leading to parenteral nutrition and/or intravenous fluids (PN/IV) dependence. Teduglutide can reduce reliance on PN/IV. Previous teduglutide systematic reviews are limited, including only data from studies suitable for meta-analysis. Here, we aim to summarize the broader literature describing the real-world outcomes of adults with SBS-IF. Methods: We conducted a systematic literature review in the Ovid Embase and MEDLINE databases to April 9, 2024, to identify publications reporting effectiveness, health-related quality of life (HRQoL), and/or safety of teduglutide in adults with SBS-IF in real-world clinical practice. Key conference proceedings were also searched. Results: Of 645 publications identified, 31 publications describing 26 unique real-world studies were included. The number of patients per study ranged from 6 to 669. All 13 studies presenting infusion frequency reported an improvement with teduglutide. In total, 21/22 studies reporting PN/IV volume observed improvement with teduglutide. Patient proportion attaining enteral autonomy ranged from 10.5% to 100% at the last time point reported (21 studies). Teduglutide showed effectiveness across anatomic groups. Improvements were observed in four studies reporting HRQoL. Safety was reported in 17 studies; the most frequently reported adverse events included abdominal pain/cramping, nausea, injection-site reactions, catheter-related sepsis/infection, and stoma complications. Conclusion: This systematic review summarizes 10 years of real-world evidence on the effectiveness, including HRQoL, and safety of teduglutide in treating adults with SBS-IF in clinical practice, across phenotypic anatomic groups including patients with stomas and patients with colon in continuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.